Journal
CHINESE JOURNAL OF CANCER RESEARCH
Volume 33, Issue 5, Pages 616-626Publisher
CHINESE JOURNAL CANCER RESEARCH CO
DOI: 10.21147/j.issn.1000-9604.2021.05.08
Keywords
Chidamide; CHOP; PTCL; frontline treatment
Categories
Funding
- Shenzhen Chipscreen Biosciences Co., Ltd.
- China National Major Project for New Drug Innovation [2017ZX09304015]
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001]
Ask authors/readers for more resources
Chidamide in combination with standard CHOP chemotherapy was well-tolerated and showed promising preliminary efficacy in previously untreated PTCL patients, supporting further clinical studies with this combination regimen for frontline treatment of PTCL.
Objective: Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for treatment-naive PTCL patients. Methods: This study was an open-label, multicenter trial composed of dose escalation and dose expansion. Patients received CHOP for six 21-d cycles and chidamide on d 1, 4, 8 and 11 in each cycle. Four dose levels of chidamide (20, 25, 30 and 35 mg) were evaluated. The primary objective was to evaluate the safety and tolerability of the combination regimen. Results: A total of 30 patients were evaluated in this study: 15 in the dose-escalation part and 15 in the dose expansion part. In the dose-escalation study, three patients were enrolled in the 35 mg chidamide cohort. One had dose-limiting toxicity with grade 3 vascular access complications, and one had grade 2 neutropenia with a sustained temperature >38 degrees C. Dose escalation was stopped at this chidamide dose level. The most common (>= 10%) grade 3 or 4 adverse events (AEs) were leukopenia (90.0%), neutropenia (83.3%), vomiting (13.3%), thrombocytopenia (10.0%) and febrile neutropenia (10.0%). No significant changes in chidamide pharmacokinetic properties were observed before and after combination treatment. The objective response rate for the 28 patients evaluable for preliminary efficacy was 89.3% (25/28), with 16 (57.1%) achieving complete response or unconfirmed complete response. The estimated median progression-free survival was 14.0 months. In summary, we chose chidamide 30 mg as the recommended dose for phase 2. Conclusions: The addition of chidamide to standard CHOP chemotherapy was tolerable with promising preliminary efficacy in previously untreated PTCL patients, which supports further clinical studies with this combination regimen for the frontline treatment of PTCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available